News

We are pleased to announce that Dr. Amy Margolis has joined the Clinical and Translational Science Institute (CTSI) as the Co-Director of Workforce Development and Director of the Investigator Career Development and Training Program.

Dr. Amy Margolis is Professor of Psychiatry and Behavioral Health at The Ohio State University. She specializes in developmental cognitive neuroscience, focusing on how environmental factors influence brain development. Dr. Margolis leads groundbreaking research exploring the impact of prenatal chemical and social exposures on cognitive development in children, aiming to uncover mechanisms that may inform interventions for learning disorders as well as other mental health problems.

Dr. Margolis brings over a decade of comprehensive knowledge, practical experience and a deep dedication to mentoring and developing the next generation of research scientists. Many of the graduate students, postdoctoral fellows and junior faculty she has mentored have gone on to successful careers as scientists in academia, government and industry. Dr. Margolis passionately believes that by creating safe places for dialogue, and infrastructure support, we can empower and engage people from historically excluded groups in the clinical and translational science workforce and in research studies.

In her new role at the CTSI, Dr. Margolis will collaborate with institutional leadership to further develop innovative programming, grant-writing resources and educational opportunities that facilitate the success of clinical and translational investigators. Dr. Margolis's interdisciplinary and collaborative approach will be an asset to the CTSI. She envisions developing new programming to complement existing initiatives, ranging from a High School STEM writing program aimed at fostering a diverse next generation of scientists to supporting mid-career faculty in the transition to full Professor .

Dr. Margolis's expertise, passion and dedication will greatly contribute to the mission of the CTSI and the advancement of today’s discoveries to improve health for all. Please join us in welcoming Dr. Amy Margolis.

Liz Klein Ph.D, MPH, Ohio State CTSI leadership member, co-authored a recent study that found that quitline coaching significantly helped young adults who vape quit.

 This initiative provides training opportunities at both NCATS and FDA.

Due to the size and complexity of Ohio State’s portfolio of more than 7000 active IRB studies, the transition from Buck-IRB to Huron will occur in phases.

Julie Johnson, PharmD, presented about our UM1 Pilot Program.

Are you aware of these changes from the NIH for 2025 applications and reviews? 

In 1976, at a moment in history when U.S. enrollment of women in medical schools had just climbed to 20%, it is notable that the chronicles of the Association of Clinical Research Professionals (ACRP) describe the first meeting of two nurses who were among the field’s earliest clinical research coordinators, Sarah Boyer and Anne LeSher, as the impetus for the formation of the Association. 

The drug development process is a collaborative effort among scientists, patients, industry sponsors, the FDA and healthcare providers.

The National Institutes of Health (NIH) has introduced key policy updates that will impact grant applications, peer reviews and post-award processes.